3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Breast Neoplasms
9
Prostatic Neoplasms
5
Neoplasms
5
Neoplasm Metastasis
4
Advanced Solid Tumors
4
Leukemia, Myeloid, Acute
3
Triple Negative Breast Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Carcinoma, Renal Cell
2
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Recurrent Squamous Cell Lung Carcinoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Myelodysplastic Syndromes
1
Lymphoma, Mantle-Cell
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Fanconi Anemia, Complementation Group D1
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Childhood Solid Tumors
1
Central Nervous System Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Breast Adenocarcinoma
1
Advanced Solid Tumor
1
Interventions
Temozolomide
88
Bevacizumab
49
Radiotherapy
36
Irinotecan
22
Magnetic Resonance Spectroscopy
21
Surgical Procedures, Operative
17
Carboplatin
17
Carmustine
15
Radiation
13
Nivolumab
11
IL13-PE38
8
Erlotinib Hydrochloride
8
Thalidomide
7
Radiotherapy, Intensity-Modulated
7
Lomustine
7
Imatinib Mesylate
7
Everolimus
7
Aminolevulinic Acid
7
sargramostim
6
Topotecan
6
O(6)-benzylguanine
6
Cyclophosphamide
6
Chemotherapy, Adjuvant
6
vandetanib
5
temsirolimus
5
fluorodopa F 18
5
Vincristine
5
Surveys and Questionnaires
5
Radiosurgery
5
Flucytosine
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Glioma
×
talazoparib
×
Clear all
NCT04740190
2025-06-11
TAC-GReD
The University of Hong Kong
Phase 2
Completed
33 enrolled